NCT01145638已完成3 期
A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 350
- 试验地点
- 1
- 主要终点
- Change in Hb Concentration
研究概览
简要总结
The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women, aged more than 18 years.
- •Subjects diagnosed with cancer (non-myeloid malignancies) receiving chemotherapy at least 1 day prior to screening and who are going to receive at least two more chemotherapy cycles.
- •Hb < 12 g/dL (7.4 mmol/L).
- •Serum Ferritin <800 ng/ml.
- •An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
- •Willingness to participate after informed consent (including HIPAA, if applicable).
排除标准
- •Anemia caused primarily by other factors than CIA.
- •IV or oral iron treatment within 4 weeks prior to screening visit.
- •Erythropoietin treatment within 4 weeks prior to screening visit.
- •Blood transfusion within 4 weeks prior to screening visit.
- •Imminent expectation of blood transfusion on part of treating physician.
- •Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis).
- •Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes or to iron sulfate).
- •Known hypersensitivity to any excipients in the investigational drug products.
- •Subjects with a history of multiple allergies.
- •Decompensated liver cirrhosis or active hepatitis (alanine aminotransferase (ALAT) > 3 times upper normal limit).
- •Active acute or chronic infections (assessed by clinical judgement and if deemed necessary by investigator supplied with white blood cells (WBC) and C-reactive protein (CRP)).
- •Rheumatoid arthritis with symptoms or signs of active joint inflammation.
- •Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, intrauterine devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches).
- •Planned elective surgery during the study.
- •Participation in any other clinical study (except chemotherapy protocol) within 3 months prior to screening.
- •Known intolerance to oral iron treatment.
- •Untreated B12 or folate deficiency.
- •Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
研究组 & 干预措施
iron isomaltoside 1000
Experimental
Iron isomaltoside intravenously as bolus or infusion
干预措施: iron isomaltoside 1000 (Drug)
iron sulphate
Active Comparator
oral iron sulphate twice a day
干预措施: iron sulphate (Drug)
结局指标
主要结局
Change in Hb Concentration
时间窗: Baseline week 4
次要结局
- Change in Hemoglobin From Baseline to Week 24(24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency AnaemiaInflammatory Bowel DiseaseNCT01017614Pharmacosmos A/S350
已完成
3 期
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis PatientsAnemiaNCT00233597AMAG Pharmaceuticals, Inc.230
已完成
3 期
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease PatientsAnemiaNCT00255437AMAG Pharmaceuticals, Inc.304
已完成
3 期
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease PatientsAnemiaNCT00255424AMAG Pharmaceuticals, Inc.304
已完成
3 期
Treatment of Women After Postpartum HaemorrhagePostpartum HaemorrhageNCT01895218Pharmacosmos A/S200